- Reports /
- Roxatidine Market
Roxatidine Market
Roxatidine Market Research Report – Segmented By Formulation (ORAL, INJECTABLE), By Application (ACIDITY, HEARTBURN, INTESTINAL ULCERS), By Region (EUROPE, ASIA-PACIFIC, LAMEA) & Region (North America, Europe, APAC, Latin America, Middle East and Africa) – Analysis on Size, Share, Trends, COVID-19 Impact, Competitive Analysis, Growth Opportunities and Key Insights from 2019 to 2027.
Table of contents
- Executive Summary
- Market Overview
- Industry Analysis
- Market Analysis
- By Formulation
- By Application
- By Region
- North America
- Europe
- Asia-Pacific
- Middle-East & Africa
- Latin America
- Company Analysis
- Competitive Analysis
- Research Methodology
- Appendix
Executive Summary
Roxatidine Market was valued at US $888.60 million in 2021 and is projected to grow at 13.08% CAGR over the forecast period to reach US $1,858.05 million by 2027. Roxatidine Market represented US $193.70 million opportunity over 2019-2021 and estimated to create US $969.45 million opportunity in 2027 over 2021.
Roxatidine from Consainsights analyses the Roxatidine Market in the Life Sciences industry over the forecast period to 2027.
Roxatidine research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.
Roxatidine segmentation includes Formulation, Application, Region and Geography.
Based on the Formulation, the Roxatidine analysis covers ORAL, INJECTABLE.
In Formulation segment, ORAL segment has highest cagr growth of 11.55%.
Based on the Application, the Roxatidine analysis covers ACIDITY, HEARTBURN, INTESTINAL ULCERS.
In Application segment, ACIDITY segment has highest cagr growth of 11.55%.
Based on the Region, the Roxatidine analysis covers EUROPE, ASIA-PACIFIC, LAMEA.
In Region segment, EUROPE segment has highest cagr growth of 11.55%.
Based on the region, the Roxatidine analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.
Key companies operating in the market include SANOFI, SUN PHARMACEUTICAL INDUSTRIES LTD., SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD., CAYMAN CHEMICAL, A S JOSHI & COMPANY, TAJ PHARMACEUTICALS LIMITED, AMGEN INC. and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.
Market Overview
Definition & Scope
The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.
The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.
The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.
Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.
Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.
As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.
Currency, Year & Forecast
The currency used in this report is USD, with the market size indicated in terms of USD million/billion.
For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.
For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.
Formulation
Introduction
In 2021, ORAL segment has the highest revenue of US $808.60 million and is expected to grow at CAGR of 11.55% by 2027 ORAL segment has highest cagr growth of 11.55%.
ORAL
ORAL segment was valued at US $632.34 million in 2019 and is projected to grow at 11.55% CAGR over the forecast period to reach US $1,690.78 million by 2027. ORAL segment represented US $176.26 million opportunity over 2019-2021 and estimated to create US $882.18 million opportunity in 2027 over 2021.
INJECTABLE
INJECTABLE segment was valued at US $62.56 million in 2019 and is projected to grow at 11.55% CAGR over the forecast period to reach US $167.27 million by 2027. INJECTABLE segment represented US $17.44 million opportunity over 2019-2021 and estimated to create US $87.27 million opportunity in 2027 over 2021.
Application
Introduction
In 2021, ACIDITY segment has the highest revenue of US $394.75 million and is expected to grow at CAGR of 11.55% by 2027 ACIDITY segment has highest cagr growth of 11.55%.
ACIDITY
ACIDITY segment was valued at US $308.70 million in 2019 and is projected to grow at 11.55% CAGR over the forecast period to reach US $825.43 million by 2027. ACIDITY segment represented US $86.05 million opportunity over 2019-2021 and estimated to create US $430.67 million opportunity in 2027 over 2021.
HEARTBURN
HEARTBURN segment was valued at US $192.46 million in 2019 and is projected to grow at 11.55% CAGR over the forecast period to reach US $514.61 million by 2027. HEARTBURN segment represented US $53.65 million opportunity over 2019-2021 and estimated to create US $268.50 million opportunity in 2027 over 2021.
INTESTINAL ULCERS
INTESTINAL ULCERS segment was valued at US $193.73 million in 2019 and is projected to grow at 11.55% CAGR over the forecast period to reach US $518.02 million by 2027. INTESTINAL ULCERS segment represented US $54.00 million opportunity over 2019-2021 and estimated to create US $270.28 million opportunity in 2027 over 2021.
Region
Introduction
In 2021, EUROPE segment has the highest revenue of US $431.60 million and is expected to grow at CAGR of 11.55% by 2027 EUROPE segment has highest cagr growth of 11.55%.
EUROPE
EUROPE segment was valued at US $337.52 million in 2019 and is projected to grow at 11.55% CAGR over the forecast period to reach US $902.48 million by 2027. EUROPE segment represented US $94.08 million opportunity over 2019-2021 and estimated to create US $470.88 million opportunity in 2027 over 2021.
ASIA-PACIFIC
ASIA-PACIFIC segment was valued at US $164.69 million in 2019 and is projected to grow at 11.55% CAGR over the forecast period to reach US $440.36 million by 2027. ASIA-PACIFIC segment represented US $45.91 million opportunity over 2019-2021 and estimated to create US $229.76 million opportunity in 2027 over 2021.
LAMEA
LAMEA segment was valued at US $192.69 million in 2019 and is projected to grow at 11.55% CAGR over the forecast period to reach US $515.21 million by 2027. LAMEA segment represented US $53.71 million opportunity over 2019-2021 and estimated to create US $268.82 million opportunity in 2027 over 2021.